Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)

An Exploratory Study on the Safety and Efficacy of Cryoablation Combined With Camrelizumab and Apatinib in the Treatment of Multiprimary Lung Cancer With Non-known Driving Genes

Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients.

Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.

Study Overview

• Status: Unknown
• Conditions: Lung Cancer
• Intervention / Treatment: Drug: Camrelizumab and Apatinib

Detailed Description

Subjects who meet the admission criteria will be treated with Camrelizumab and Apatinib until disease progression, intolerable toxicity, death, withdrawal of the patient or the researchers determined that the drug must be discontinued.

The primary end point of this study is safety of cryoablation combined with carillizumab and apatinib for MPLC. The secondary endpoints include objective response rate, disease control rate, time to progression, progression free survival and overall survival. Exploratory endpoint is to explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib.

• Study Type: Interventional
• Enrollment (Anticipated): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. clinical and pathological diagnosis of muitiple primary lung cancer.
2. more than three pulmonary nodules and without lymph node metastasis.
3. the maximum lesion less than three centimeters in diameter.
4. No more than one operation, and remains more than two pulmonary nodules which pathological confirmed were MIA or AIS.
5. at least one measurable lesion conforming to RECIST v1.1 standard was left after cryotherapy.
6. male or female, age 18 to 75 years old.
7. the ECOG PS score was 0 or 1.
8. expected survival is more than 12 weeks.
9. functions of vital organs and bone marrow meet the following requirements: A. ANC ≥1.5× 109/L, PLT ≥100× 109/L, HGB ≥9 g/dL; B. TBIL ≤1.5 ULN, ALT and/or AST ≤2.5 ULN, ALB ≥2.8 g/dL; C. Cr ≤1.5× ULN, or creatinine clearance rate ≥40 mL/min
10. subject and subject's sexual partner shall use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.
11. subject must sign theinformed consent.

Exclusion Criteria:

1. patients with EGFR mutations and ALK rearrangement.
2. cannot be treated with cryoablation: diffuse lesions in both lungs, extensive pleural metastasis with large amount of pleural effusion, tumor adjacent to mediastinal large vessels or surrounding large vessels.
3. have previously received anti-pd-1, anti-pd-l1, anti-ctla-4 antibodies or any other antibodies or drugs that target T cell co-stimulation or immune checkpoint pathways.

4. received the following treatment Within four weeks before enrollment:

   • received systemic anti-tumor therapy, such as chemotherapy, targeted therapy and immunotherapy;
   • receive any investigational medication;
   • receive a large dose of immunosuppressive drugs (systemic glucocorticoid exceeding 10 mg/ temprednisone or its equivalent);
   • receive live attenuated vaccine;
   • major surgery or unhealed surgical wounds, ulcers, or fractures.
5. known or suspected active autoimmune diseases (congenital or acquired).
6. allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
7. allergy to any component of monoclonal antibody preparation.
8. interstitial lung disease.

9. suffering from other uncontrolled serious diseases, including but not limited to:

   • severe infections in the active phase or with poor clinical control;
   • HIV infection (HIV antibody positive);
   • acute or chronic active hepatitis B (HBV DNA positive) or acute or chronic active hepatitis C (HCV antibody positive);
   • active tuberculosis;
   • grade iii-iv congestive heart failure (New York cardiology association classification), poorly controlled and clinically significant arrhythmia;
   • uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg);
   • any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, occurred within 6 months;
   • diseases requiring anticoagulant therapy with farfarin (coumarin);
   • uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued bisphosphate therapy;

   • accompanied by other malignant tumors (except those that have been cured, such as carcinoma in situ of the cervix, non-melanoma skin cancer, etc.).

     10. The participants were judged to be unsuitable for the study by investigator.

     11. Pregnant or nursing women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: treatment group; Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years	Drug: Camrelizumab and Apatinib; Camrelizumab, iv, Q3W; Apatinib, po, QD; Other Names: cryoablation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety score	The occurrence of grade 3 to 5 adverse reactions was assessed by CTC AE v5.0	three weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	objective response rate	six weeks
DCR	Disease control rate	six weeks
PFS	progression free survival	six weeks
OS	Overall survival	six weeks
DOR	Duration of response	six weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
biomarker	To explore biomarkers in tumor tissue and blood that could potentially predict the efficacy of Camrelizumab and Apatinib like PD-L1, ctDNA, CEA， CA125， CA153.	three months

Collaborators and Investigators

• Sponsor: ShiYue Li

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): December 1, 2019
• Primary Completion (ANTICIPATED): December 1, 2021
• Study Completion (ANTICIPATED): December 1, 2022

Study Registration Dates

• First Submitted: December 3, 2019
• First Submitted That Met QC Criteria: December 15, 2019
• First Posted (ACTUAL): December 17, 2019

Study Record Updates

• Last Update Posted (ACTUAL): December 17, 2019
• Last Update Submitted That Met QC Criteria: December 15, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Keywords: Apatinib; Camrelizumab; MPLC
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Apatinib
• Other Study ID Numbers: 2019-62

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No